An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Inclusion Criteria: * Patients who meet any one of the following. Patients with a diagnosis of parathyroid carcinoma and corrected serum calcium \> 11.3 mg/dL at the latest screening test. Patients with intractable PHPT (defined as follows: impossible to localize parathyroid tumor before initial surgery or in relapse after surgery, or impossible to perform parathyroidectomy (PTx) for complications, and corrected serum calcium is \> 12.5 mg/dL at the screening test). * Patients who provided their voluntary written informed consent to participate in the study. Exclusion Criteria: * Patients diagnosed with malignant tumor except for parathyroid carcinoma, nonmelanoma skin cancer, and carcinoma in situ of the cervix within 5 years before enrollment. * Patients receiving anticancer chemotherapy except for the treatment of parathyroid carcinoma. * Patients diagnosed with hypercalcemia associated with malignant tumors other than parathyroid carcinoma. * Patients who had hypersensitivities to cinacalcet HCl preparations or vehicles.